Amarantus update
To achieve spectacular performance speculating in the stock market, you must arrive at the party before the crowd. It may be a simple strategy, but it can propel the performance of your stocks past the mediocre results the majority of investors see each year. Instead of waiting to get involved once a stock is up 30 or 40 percent and seeing the same lack luster returns as the masses get on board with a promising biotech that has overwhelming possibilities.
Investors with their ear to the ground and their eyes on the past month’s charts have heard the low hum of AMBS (Amarantus Biosciences) quickly rise to a steady rumble. This burgeoning development-stage biotechnology company has gained consistently and shows no signs of slowing its pace. With last month’s coverage beginning at .11 a share, AMBS has since peaked at an impressive .50 and settled into a robust .18 after flirting with the above .20 range. In addition, current RSI figures – often responsible for swaying key market insiders – place the stock right at the heart of the ripest zone for trading. Given the trend of positive growth and a market capitalization of only $11 million, we believe its current trading price represents only a small fraction of the potential future value of an investment in AMBS.
But the strengths of AMBS are neither fleeting nor merely in the numbers. Amarantus Bioscience’s primary focus is in developing MANF, a disease-modifying therapeutic protein, which decreases the activity of apoptosis-causing enzymes caused by Parkinson’s and other apoptosis-related disorders. Late last month the company was granted a Notice of Allowance from the United States Patent & Trademark Office for its discovery of MANF, which broadens protection of the company’s proprietary goals and effectively increases long-term shareholder value.
Amarantus’ unique opportunity to develop this particular protein into a powerful biologic therapy represents an extremely high revenue potential in the Parkinson’s disease market, which is currently estimated at well over $2 billion and is set to double in the next 20 years. The company has so firmly staked its claim as a leader in the area of Parkinson’s research and treatment development, that pre-clinical experiments conducted by Amarantus earlier in the year were funded by a handsome grant from the Michael J. Fox Foundation for Parkinson’s Research. In addition, the PhenoGuard Cell Lines portfolio obtained for research purposes by Amarantus contains a full 88 strains, and the MANF protein was discovered in the very first cell line. This all equates to an unfathomable potential for growth.
It’s little wonder, then, why that + symbol has continually found itself next to AMBS in the quotes each morning. The combination of CEO Gerald Commissiong’s incisive business strategy with Amarantus’ in-house team of experienced neuroscientists and Parkinson’s researchers is a winning business formula. In fact, November 1st saw Amarantus announce a new expansion and diversification of its corporate strategy by way of identifying complementary assets and unmet medical needs within its core areas of neuroscience research.
“Amarantus intends to seize upon the opportunities created by inefficiencies in the marketplace for Parkinson’s disease and Central Nervous System disorder-related product development programs to dramatically alter the paradigm for patients suffering from these terrible diseases,” said Commissiong.
While the Management Team has presided over the company’s persistent market growth, the Scientific Advisory Board is responsible for examining every facet of MANF research and treatment. Dr. John Commissiong, Chief Scientific Officer of Amarantus, has also emphasized the effectiveness MANF may ultimately display to treat Parkinson’s.
“Since 2003, 14 papers have been published in highly-respected peer-reviewed journals describing MANF’s ability to rescue neurons from death in a variety of cellular and animal models of CNS disease,” said Dr. John W. Commissiong, Chief Scientific Officer of Amarantus who discovered MANF. “The data presented at the Scientific Advisory Board meeting confirms critical aspects of that work and will allow the Company to focus the MANF Parkinson’s development program on the required protocols to gain regulatory approval to initiate human clinical studies.”
The findings are clear that MANF displays vast potential as an important agent in the future treatment of Parkinson’s and other apoptosis-related disorders. As Amarantus firmly establishes itself in all corners of this blossoming market, investors with their eyes on the market would be well advised to take notice of AMBS.
Trades AMBS on the OTC Bulletin Board.Tweet
